The U.S. Food and Drug Administration (FDA) has approved a new oral medication called dapagliflozin for adults with type 2 diabetes. This pill, known as an SGLT2 inhibitor, works by helping the kidneys remove extra sugar from the body through urine. It is approved for two main purposes: to improve blood sugar control alongside diet and exercise, and to reduce the risk of hospitalization for heart failure in patients who also have heart disease or several risk factors for it.
This approval is significant because it recognizes that this single medication can address two major aspects of health for a specific group of people with type 2 diabetes. For patients at higher risk for heart problems, it offers a treatment option that may help manage their diabetes while also providing potential heart protection. It reflects a growing understanding of how diabetes and heart health are closely connected.
It is important to know that this drug is not for everyone. The FDA label states it is not recommended for people with type 1 diabetes. It is also not recommended for controlling blood sugar in people with type 2 diabetes who have more advanced kidney disease, as it may not work well for that purpose in those cases.
As with any new medication approval, this news provides doctors with another tool to consider for their patients. The most important step for anyone interested in this treatment is to have an honest conversation with their own doctor. A healthcare provider can review an individual's full health history to determine if this medication might be a suitable option for them.